



## **SMFM Responds to New Data on Mild Chronic Hypertension and Pregnancy**

**April 2, Washington, DC** – The Society for Maternal-Fetal (SMFM) released the following statement in response to the published results of “Treatment for Mild Chronic Hypertension during Pregnancy,” in the [\*New England Journal of Medicine\*](#).

“SMFM has supported the [2019 guidelines](#) from the American College of Obstetricians and Gynecologists, which do not recommend pharmacologic treatment for mild chronic hypertension during pregnancy. Historically, this recommendation results from a lack of data confirming maternal or perinatal benefit with treatment and concerns that antihypertensive therapy may impair fetal growth.

The Chronic Hypertension and Pregnancy (CHAP) Trial provides new data regarding the benefits and safety of pharmacologic therapy for mild chronic hypertension in pregnancy. SMFM’s Publications Committee is currently reviewing the results of the trial and will issue revised clinical guidance, as appropriate.”

###

### **About SMFM**

The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients. For more information, visit [SMFM.org](http://SMFM.org).